LCBSX
Price
$50.41
Change
-$0.06 (-0.12%)
Updated
Sep 20 closing price
RRMGX
Price
$97.44
Change
-$0.69 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

LCBSX vs RRMGX

Header iconLCBSX vs RRMGX Comparison
Open Charts LCBSX vs RRMGXBanner chart's image
ClearBridge Select FI
Price$50.41
Change-$0.06 (-0.12%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth R
Price$97.44
Change-$0.69 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
LCBSX vs RRMGX Comparison Chart
Loading...
VS
LCBSX vs. RRMGX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LCBSX is a StrongBuy and RRMGX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RRMGX has more cash in the bank: 31.4B vs. LCBSX (3.33B). LCBSX (0.00) and RRMGX (0.00) have matching dividends . LCBSX was incepted earlier than RRMGX: LCBSX (12 years) vs RRMGX (22 years). RRMGX is a more actively managed with annual turnover of: 21.70 vs. LCBSX (20.00). LCBSX has a lower initial minimum investment than RRMGX: LCBSX (0) vs RRMGX (2500). LCBSX annual gain was more profitable for investors over the last year : 28.29 vs. RRMGX (13.62). LCBSX return over 5 years is better than : 84.40 vs. RRMGX (9.23).
LCBSXRRMGXLCBSX / RRMGX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence12 years22 years-
Gain YTD13.6468.605159%
Front LoadN/AN/A-
Min. Initial Investment02500-
Min. Initial Investment IRAN/AN/A-
Net Assets3.33B31.4B11%
Annual Yield % from dividends0.000.00-
Returns for 1 year28.2913.62208%
Returns for 3 years-8.85-16.2854%
Returns for 5 years84.409.23915%
Returns for 10 years238.2733.74706%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OII26.020.16
+0.62%
Oceaneering International
COTY9.19-0.20
-2.13%
COTY
CLCO11.05-0.30
-2.64%
Cool Company Ltd
QLGN0.17-0.01
-3.55%
Qualigen Therapeutics
PRPH2.34-0.17
-6.77%
ProPhase Labs